Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Shanghai Junshi Bioscience (1877 HK): Tuoyi Holds Momentum Steady As a Rock, Losses Narrow in 1H

Shanghai Junshi Bioscience (1877 HK): Tuoyi Gains Momentum; Losses Narrow; New Geographies Open Up

Shanghai Junshi Bioscience (1877 HK): Key Drug on High Trajectory; Geopolitical Tension Spoils Party

Equity Capital Markets

Shanghai Junshi Biosciences  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-junshi-biosciences-co-838d3eb3-3e0d-45f0-a9c5-ab0764709221" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Biosciences (1877 HK)</a> is placing 41M H shares for subscription at HK$25.35 per H Share.</li>
<li>Shanghai Junshi intends to use 70% of the net proceeds from the placement for innovative drug development and balance 30% for general corporate purposes such as replenishment of working capital.</li>
<li>Early green shoots in the form of lower R&amp;D expenses and narrowing losses. Junshi offers for a good long-term bet as the company turning profitable will take some time.</li>
</ul>



Shanghai Junshi Biosciences (1877 HK) is placing 41M H shares for subscription at HK$25.35 per H Share.
Shanghai Junshi intends to use 70% of the net proceeds from the placement for innovative drug development and balance 30% for general corporate purposes such as replenishment of working capital.
Early green shoots in the form of lower R&amp;D expenses and narrowing losses. Junshi offers for a good long-term bet as the company turning profitable will take some time.


Shanghai Junshi Bioscience (1877 HK): Placement Good, A Long Term Bet for Sure